Showing results (281-290 of 357) with videos related to

Sort By:
Pageof 36
Cell Chemical Biology|December 22, 2023
A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cellsJackson J Peterson, Catherine A Lewis, Samuel D Burgos, et al.
Plos Pathogens|February 26, 2021
Epigenomic characterization of latent HIV infection identifies latency regulating transcription factorsStuart R Jefferys, Samuel D Burgos, Jackson J Peterson, et al.
Cell|March 30, 2020
Curing HIV: Seeking to Target and Clear Persistent InfectionDavid M Margolis, Nancie M Archin, Myron S Cohen, et al.
International Journal of Molecular Sciences|March 25, 2022
2-Aminoimidazoles Inhibit Mycobacterium abscessus Biofilms in a Zinc-Dependent MannerJuan M Belardinelli, Wei Li, Kevin H Martin, et al.
Plos One|July 28, 2017
2-aminoimidazoles potentiate ß-lactam antimicrobial activity against Mycobacterium tuberculosis by reducing ß-lactamase secretion and increasing cell envelope permeabilityAlbert B Jeon, Andrés Obregón-Henao, David F Ackart, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
Open Forum Infectious Diseases|May 17, 2024
Sequence Analysis of Inducible, Replication-Competent Virus Reveals No Evidence of HIV-1 Evolution During Suppressive Antiviral Therapy, Indicating a Lack of Ongoing Viral ReplicationSook-Kyung Lee, Amy Sondgeroth, Yinyan Xu, et al.
HIV Clinical Trials|August 14, 2003
Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adultsPeter J Ruane, David M Parenti, David M Margolis, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 12, 2016
Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialJeffrey M Jacobson, Jean-Pierre Routy, Seth Welles, et al.
Journal of Virology|April 8, 2011
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activationSifei Xing, Cynthia K Bullen, Neeta S Shroff, et al.
Pageof 36